Iron-Magnesium Hydroxycarbonate (Fermagate)
- 1 February 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 4 (2), 401-409
- https://doi.org/10.2215/cjn.02630608
Abstract
Background and objectives: This phase II study tested the safety and efficacy of fermagate, a calcium-free iron and magnesium hydroxycarbonate binder, for treating hyperphosphatemia in hemodialysis patients. Design, setting, participants, & measurements: A randomized, double-blind, three-arm, parallel-group study compared two doses of fermagate (1 g three times daily or 2 g three times daily with placebo). Sixty-three patients who had been on a stable hemodialysis regimen for ≥3 mo were randomized to the treatment phase. Study medication was administered three times daily just before meals for 21 d. The primary endpoint was reduction in serum phosphate over this period. Results: In the intention-to-treat analysis, mean baseline serum phosphate was 2.16 mmol/L. The fermagate 1- and 2-g three-times-daily treatment arms were associated with statistical reductions in mean serum phosphate to 1.71 and 1.47 mmol/L, respectively. Adverse event (AE) incidence in the 1-g fermagate arm was statistically comparable to the placebo group. The 2-g arm was associated with a statistically higher number of patients reporting AEs than the 1-g arm, particularly gastrointestinal AEs, as well as a higher number of discontinuations, complicating interpretation of this dose's efficacy. Both doses were associated with elevations of prehemodialysis serum magnesium levels. Conclusions: The efficacy and tolerability of fermagate were dose dependent. Fermagate showed promising efficacy in the treatment of hyperphosphatemia in chronic hemodialysis patients as compared with placebo in this initial phase II study. The optimal balance between efficacy and tolerability needs to be determined from future dose-titration studies, or fixed-dose comparisons of more doses.Keywords
This publication has 25 references indexed in Scilit:
- Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysisKidney International, 2005
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE studyKidney International, 2004
- Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcificationClinical Nephrology, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Phosphate removal and hemodialysis conditionsKidney International, 2001
- Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failureAmerican Journal of Kidney Diseases, 2000
- Successful Control of Hyperparathyroidism in Patients on Continuous Ambulatory Peritoneal Dialysis Using Magnesium Carbonate and Calcium Carbonate as Phosphate BindersNephron, 1993
- The Use of Magnesium-Containing Phosphate Binders in Patients with End-Stage Renal Disease on Maintenance HemodialysisNephron, 1982
- Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failureArchives of Internal Medicine, 1976